Bavencio (avelumab) is a brand-name drug that’s prescribed for certain types of cancer in adults and some children. Bavencio comes as an intravenous (IV) infusion that’s given by a healthcare ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from KEYTRUDA ...

Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...

Pfizer Inc. PFE along with Germany-based partner Merck KGaA announced that the FDA has approved a supplemental biologics license application (sBLA) for their PD-L1 inhibitor Bavencio (avelumab). The ...

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows. Thursday, the companies said Bavencio (avelumab) had failed to outdo chemo ...

There was no improvement in overall survival found in patients with gastric or gastroesophageal cancer who received Bavencio (avelumab) after induction of chemotherapy, compared to those who continued ...

Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell ...

The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, ...

BAVENCIO is currently approved for patients with MCC in 50 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment. In the US ...

ROCKLAND, Mass. and NEW YORK, Dec. 11, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today ...

Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only cancer ...

Bavencio (avelumab) is a prescription drug that treats certain skin, kidney, and bladder cancers. The drug comes as a solution that a healthcare professional injects by intravenous (IV) infusion. You ...